This document discusses the financial implications of proposed pharmacare models in Canada. It summarizes different views on what implementing universal pharmacare may cost and save. While some estimates suggest overall drug costs could be reduced by billions, others argue these savings may be overestimated once factors like drug price negotiations and impacts on private benefits are considered. The document also notes many unknowns remain around the potential economic and operational impacts of establishing a national pharmacare program in Canada.